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The basic mechanism for idiopathic FSGS still is obscure. Indirect evidence in humans and generation of FSGS by oxidants
in experimental models suggest a role of free radicals. In vitro studies demonstrate a main role of plasma albumin as
antioxidant, its modification representing a chemical marker of oxidative stress. With the use of complementary liquid
chromatography electron spray ionization tandem mass spectrometry (LC-ESI-MS/MS) and biochemical methods, plasma
albumin was characterized in 34 patients with FSGS; 18 had received a renal transplant, and 17 had IgMmesangial deposition.
Patients with FSGS that was in remission or without recurrence after transplantation had normal plasma albumin, and the
same occurred in patients with primary and secondary nephrites and with chronic renal failure. In contrast, patients with
active FSGS or with posttransplantation recurrence had oxidized plasma albumin. This finding was based on the character-
ization of albumin Cys 34 with an mass-to-charge ratio of 511.71 in triple charge that was consistent with the formation of a
cysteic acid carrying a sulfonic group (alb-SO3
). The exact mass of albumin was increased accordingly (48 Da) for
incorporation of three oxygen radicals. Direct titration of the free sulfhydryl group 34 of plasma albumin and electrophoretic
titration curves confirmed loss of free sulfhydryl group and formation of a fast-moving isoform in all cases with disease
activity. This is the first demonstration of in vivo plasma albumin oxidation that was obtained with an adequate structural
approach. Albumin oxidation seems to be specific for FSGS, suggesting some pathogenetic implications. Free radical
involvement in FSGS may lead to specific therapeutic interventions.
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F SGS is a degenerative disease of the kidney that ischaracterized by focal accumulation of extracellular ma-trix in glomeruli. It is a heterogeneous condition that
includes different variants (1–4), possible genetic background
(5), and variable response to drugs that modify long-term out-
come (6). The basic lesion ranges from minimal glomerular
involvement to segmental-global glomerulosclerosis that prob-
ably represents an evolutionary stage in patients who are un-
responsive to drugs (1,4). On clinical grounds, FSGS usually has
an abrupt onset with heavy proteinuria, hypoalbuminemia,
and frequent progression to renal failure. Notwithstanding
some recent advances on the characterization of genes that are
responsible for congenital FSGS (7–11), little is known of the
pathogenesis of the idiopathic form. The disease typically pre-
sents clinical recurrences after infectious episodes and a re-
markable percentage of 30 to 50% of patients who have FSGS
and receive renal allograft have posttransplantation recurrence
(12–15). Abnormal T cell responses, have been suggested to be
involved in the pathogenesis of the idiopathic form and in
posttransplantation recurrences but remain poorly defined and
lack specificity (16). On the basis of the rapid posttransplanta-
tion recurrence, an implication of circulating plasma factors
that persist over time and modify glomerular permeability to
proteins long has been suspected (13,14). Unfortunately, the
identification and the characterization of the circulating factors
have been elusive (17,18), and, more recently, other pathoge-
netic mechanisms have been proposed (19).
In an attempt to elucidate the pathogenesis of FSGS, we
embarked on a proteomics approach to study plasma proteins
in these patients. Our previous studies in patients with FSGS
(20) demonstrated massive oxidation of plasma albumin, re-
sulting in modification of the structure of the protein. We
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proposed that massive oxidation plays a role in the pathogen-
esis of the proteinuria that is associated with FSGS. In this
study, we devised a mass spectrometry technique for analysis
of native plasma albumin that is more reproducible and abol-
ished the need for chemical manipulation of the protein. The
structural analysis of albumin then was extended to a wide
cohort of patients with nephrotic syndrome and to patients
with posttransplantation recurrence of FSGS. Children who
had other forms of primary and secondary glomerulonephritis
and/or chronic renal failure (end-stage renal failure [ESRF])
and were undergoing various treatments also were studied to
define specificity of our structural approach. New method-
ologic assays also were developed to titrate free sulfhydryl
group (SH) of Cys 34 and to determine the occurrence of
neutral to acid transition (N-A) in large-scale screening studies.
Materials and Methods
Chemicals
Acrylamide and ampholine were from Amersham Bioscience (Upp-
sala, Sweden); N,N-methylenebisacrylamide, SDS, N,N,N,N-tetram-
ethylethylenediamine, and electrophoresis calibration standard pro-
teins were from Bio-Rad Laboratories (Hercules, CA). All other
chemicals, of analytical and electrophoretic grade, were purchased
from BDH (Poole, UK). Solutions were prepared fresh using Milli-Q
(Millipore, Milan, Italy).
Patients
FSGS/IgM. Thirty-four patients with FSGS, 18 of whom received
a renal transplant and 17 of whom had IgM mesangial proliferative
glomerulonephritis, were enrolled in the study (Tables 1 and 2). Twelve
patients of the FSGS group were presenting nephrotic syndrome at the
time of the enrollment; four had been in stable remission in the previ-
ous 2 yr. Eleven patients of the group with mesangial IgM deposits
were presenting florid proteinuria and nephrotic syndrome at the time
of the study, and the remaining six were in stable remission. The
general criteria for enrollment were (1) availability of a clear histology
diagnosis on the basis of accepted criteria and (2) absence of familiarity
and/or relevant mutations of slit diaphragm genes (NPHS2, CD2AP,
and ACTN4). Nephrotic syndrome was defined by the presence of
florid proteinuria 40 mg/h per m2. Renal biopsies were processed by
standard procedures for light microscopy, immunofluorescence stud-
ies, and electron microscopy. Clinical and pathologic features (e.g.,
gender, age at onset of proteinuria, treatment, evolution toward renal
failure, renal transplant) are reported in Tables 1 and 2. Patients with
FSGS and IgM and with active proteinuria were receiving treatment
with steroids alone (at variable dosages) or in association with cyclo-
sporin and with angiotensin-converting enzyme inhibitors (ACEi). Ste-
roids were given in a starting dosage of prednisolone 2 mg/kg fol-
lowed by a gradual taper (21). Cyclosporin was administered at 5
mg/kg starting dosage, followed by dosage adjustment to maintain
cyclosporin serum levels between 50 and 100 ng/ml (6). Six patients of
the stable remission groups with either FSGS or IgMwere still receiving
cyclosporin; ACEi was used in one. Eighteen children with FSGS had
developed ESRF and had received a cadaver renal transplant. Immu-
nosuppression therapy in these patients included tacrolimus or cyclo-
sporin, mycophenolate mofetil, and steroids. Fourteen patients of this
cohort had posttransplantation recurrence of proteinuria that was
treated with plasmapheresis (1.5-ml plasma exchange with albumin as
the unique replacement protein) in all but one patient and was associ-
ated with cyclophosphamide 2 mg/kg for 2 mo in one patient.
ESRF. Nine patients who had chronic renal failure and were un-
dergoing various treatments were enrolled. One was a child (patient 1),
two were adolescents (patients 2 and 9), and six were young adults who
developed ESRD for various reasons (Table 3). The therapeutic ap-
proach was hemodialysis in six cases, and two patients were main-
tained on a conservative treatment.
Membranous Glomerulonephritis. Eight patients had received a
diagnosis of membranous nephropathy and were all in the proteinuric
phase of the disease (Table 4). All but one were adults and were
presenting a variable degree of proteinuria from 1 to 8 g/d. Patients
with membranous glomerulonephritis (MGN) were receiving steroids
as single drug (1 to 2 mg/kg) or in combination with immune suppres-
sors (22); in some cases, ACEi (ramipril 5 to 8 mg/m2) had been
associated.
Membrane Proliferative Glomerulonephritis. Four patients had
a histology diagnosis of membrane proliferative glomerulonephritis
(MPGN) that presented with proteinuria, hematuria, and normal renal
function without arterial hypertension (Table 4). All were receiving
prednisolone (1 mg/kg) for at least 2 mo.
IgA. Five patients had a recent diagnosis of IgA in the absence of
relevant proteinuria. Only one was treated with steroids; in three cases,
it was used in a scheme with ACEi (Table 4).
Normal Control Subjects. The control group consisted of 18
healthy adult control subjects.
In all cases plasma was obtained in the morning after an overnight
fast. In patients with posttransplantation recurrence, plasma was ob-
tained at the onset of proteinuria and during the follow-up. Morning
fresh urine was collected in sterile condition without additive and
frozen at 80°C within 1 h. Plasma was frozen within 1 h and was
maintained at 80°C under vacuum. Appropriate informed consent
was obtained from all patients in the study.
Purification of Albumin from Healthy Donors and Patients
Albumin was purified from plasma of healthy donors and patients
with FSGS by preparative continuous monodimensional PAGE electro-
phoresis (total acrylamide concentration  4 to 12%) in native condi-
tions with 2-mm gel spacers. All purification steps were performed in
a native condition to prevent structural modifications according to
Margolis and Kenrick (23). One milliliter of serum was applied to gel,
and electrophoresis was run in Tris-borate-EDTA (80/90/2.5 mM) for
12 h with 16 mA at 12°C. Albumin was desorbed from acrylamide by
gentle pestle and was maintained in PBS at 4°C for 24 h with two
changes of the solution.
Liquid Chromatography Electron Spray Ionization Tandem
Mass Spectrometry (LC-ESI-MS/MS) for Tryptic Digest
Characterization
Albumin after purification was delipidated first in a methanol:ac-
etone:tributyl phosphate (1:12:1) with gentle agitation at room temper-
ature overnight and then was digested by trypsin. Trypsin was added
at an enzyme substrate ratio of 1:30 (wt/wt) in a solution of 100 mM
ammonium bicarbonate and 1 mM CaCl2 (pH 8.5). After overnight
incubation at 37°C, the reaction was stopped with formic acid to pH 2.
All mass spectrometric measurements were performed using an LTQ
linear trap mass spectrometer (Thermo Electron, San Jose, CA) coupled
to an HPLC Surveyor (Thermo Electron) and equipped with a Jupiter
C18 column 250  1 mm (Phenomenex, Torrance, CA). Peptides were
eluted from the column using an acetonitrile gradient, 5% B for 6 min
followed by 5 to 90% B within 109 min (eluent A: 0.1% formic acid in
water; eluent B: 0.1% formic acid in acetonitrile) at a flow rate of 50
l/min. The column effluent was directed into the electrospray source.
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The spray voltage was 5.0 kV. The capillary of ion trap was kept at
200°C, and the voltage was kept at 2.85 V. Spectra were acquired in
automated MS/MS mode: Each full MS scan (in the range 400 to 1800
mass-to-charge ratio [m/z]) was followed by five MS/MS of the most
abundant ions; mass that had been analyzed more than two times this
way was automatically taken up into an exclusion list for 30 s. Com-
puter analysis of peptide MS/MS spectra was performed using Bio-
works software, version 3.2 (Thermo Electron) and searched against an
ALB protein database. Peptide MS/MS assignments were filtered ac-
cording to the following criteria: cross-correlation (Xcorr)  1.9 for the
singly charged ions, Xcorr 2.2 for doubly charged ions, and Xcorr 3.7
for triply charged ions; peptide probability 0.001; change in correla-
tion value (Cn) 0.1; and percentage of ions 30%. For all protein,
two missed cleavages was allowed.
ESI-MS for Exact Mass
Albumin-containing solutions were injected manually (5 l) into an
on-line flow, using a CapLC system (Micromass, Waters, Milford, MA)
coupled with a nano-ESI-Q-TOF (quadrupole–time-of-flight) instru-
ment (Micromass, Waters). The sample was eluted at 1 l/min on a C4
precolumn LC-Packings, 300 m inner diameter  20 mm. Elution was
achieved isocratically by H2O/ACN 50/50 both with 0.1% TFA and
directed into a mass spectrometer equipped with a nano-Lock-Spray
source. A 2500- and 50-V tension was applied to the PicoTip capillary
(PicoTip Emitter, tip 10  1 m; New Objective, Woburn, MA) and
cone voltage, respectively, and the positive ion mode for ion scan
experiment was used to monitor the 700- to 2200-m/z range. Data
analysis was performed using Masslynx version 4.0 (Micromass/Wa-
ters). The data collected were examined for multiply charged protein
Table 1. Clinical and biochemical parameters in 33 children with idiopathic nephrotic syndrome subdivided
according to renal pathologya
Patient Gender Age(yr)
Age at Onset
(yr)
Proteinuria
(g/24 h)
Serum
Creatinine
(mg/dl)
Serum
Albumin
(g/dl)
Therapy
FSGS
1 M 9 1 7 0.4 1 St/ACEi
2 M 11 7 3 1.1 2.2 CsA
3 M 10 4 4 1.1 1.5 St
4 M 10 4 4 0.8 1.7 St
5 M 15 5 5 1.2 1.1 St
6 M 5 3 2 1.2 2.1 St/ACEi
7 M 2 2 4 0.8 1.2 CsA/ACEi
8 M 20 7 3 2.6 2 St
9 F 7 6 4 1.2 2 CsA
10 F 10 5 4 1 1.2 CsA
11 F 11 3 5 1.5 1.1 CsA/ACEi
12 F 9 1 3 0.7 2.1 St
13 M 14 2 0.4 0.7 4.4 CsA
14 M 12 1 0.1 0.3 4.4 CsA
15 M 22 7 0.1 0.5 4 ACEi
16 M 8 2 0.2 0.5 4.8 CsA
IgM
1 M 5 1 8 0.8 0.9 CsA
2 M 7 3 2 0.2 1.7 CsA
3 M 9 8 5 0.7 1.4 St/ACEi
4 M 3 2 5 0.3 2.2 St/ACEi
5 M 10 4 6 0.6 1.3 CsA
6 M 4 1 4 0.4 1.3 CsA
7 M 8 4 7 0.4 1.6 St
8 M 6 1 3 0.6 1 St
9 F 6 6 8 0.7 1.3 St
10 F 8 2 2 0.3 1.3 St/ACEi
11 F 16 4 5 0.5 1.3 CsA/ACEi
12 M 20 5 0.2 0.4 4.5 St
13 M 4 1 0.1 0.3 4.3 CsA
14 M 12 3 0.2 0.5 4.4 CsA
15 M 12 2 0.2 0.5 4.3 CsA
16 F 8 1 0.1 0.2 4.4 –
17 F 16 3 0.1 0.7 4.1 –
aTen patients were evaluated during stable remission of nephrotic syndrome. induced by drugs; in these, plasma had been
collected after at least 6 mo of normal urine. ACEi, angiotensin-converting enzyme inhibitor; CsA, cyclosporine; St, steroids.
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spectra, which then were integrated to provide a single combined
spectrum for the protein injected. A maximum entropy deconvolution
algorithm (MaxEnt1) was used to deconvolute multiply charged spec-
tra and produce molecular mass spectra.
Electrophoretic Titration Curves
For electrophoretic titration curves, we used total plasma in antico-
agulant citrate dextrose. Titration was performed according to Bruschi
et al. (24). Both methods for electrophoresis runs and calculations have
been described previously (24,25).
“In Gel” Determination of Free SH Accessibility
Free SH group titration in plasma albumin was done with the male-
imide-PEO2-Biotin (biotinyl-3-maleimidopropionamidyl-3,6-dioxact-
anediamine) assay (Pierce, Rockford, IL) according to the manufactur-
er’s instructions. After reaction with maleimide- PEO2-Biotin, plasma
proteins first were separated in monodimensional polyacrylamide gels
performed according to Laemmli (26) without mercapto-ethanol. After
electrophoresis (total acrylamide concentration  5 to 16%; degree of
cross-link  2.67%) reactivity of SH groups with maleimide was al-
lowed at pH 6.5 for 2 h at 37°C. Streptavidin that was conjugated with
Table 2. Clinical parameters in 18 children who had idiopathic FSGS and developed ESRF and received a renal
graft.
Patient
No. Gender
Onset
(yr)
ESRF
(yr)
Transplantation
(yr)
Days for
Recurrence Therapy Outcome
1 M 4.2 6 7 1 PL Stable proteinuria
2 F 4.3 7 8 7 – Stable proteinuria
3 M 10.5 14 15 1 PL Remission
4 F 4.2 12 13 9 PL Remission
5 M 9.6 11 13 15 PL Remission
6 M 12.3 30 34 15 PL Stable proteinuria
7 F 13.7 18 19 3 PL Frequent recurrence
8 M 0.6 4 5 22 PL Remission
9 M 2.2 4 6 1 PL Remission
10 M 14 14 16 30 PL/Cy ESRF
11 M 11 11 15 600 PL Normal function
12 F 36 45 50 30 PL Stable proteinuria
13 F 28 32 33 1 PL ESRF
14 F 5 28 32 4 PL Nephrectomy
No recurrence
1 F 5.2 8 10 – – –
2 F 3.0 6 9 – – –
3 F 6.3 7 8 – – –
4 M 5.2 16 17 – – –
aFourteen patients of this cohort presented recurrence of proteinuria and were treated with a combination of
plasmapheresis and cyclophosphamide. The other four patients had stable and prolonged good outcome. Cy,
cyclophosphamide; ESRF, end-stage renal failure; PL, plasmapheresis.
Table 3. Clinical and biochemical parameters in nine patients with chronic renal failure from various renal
pathologiesa
ESRF Gender Age(yr) Renal Pathology
Serum Creatinine
(mg/dl)
Serum Albumin
(g/dl) HD/PD
1 F 2 Dysplasia 3 4 –
2 M 12 ARPKD 4 3.5 –
3 M 32 Terminal kidney – 3.2 HD
4 M 26 Reflux nephropathy – 4.1 HD
5 M 24 Reflux nephropathy – 4.2 HD
6 M 24 TIN – 3.8 HD
7 F 21 LES – 4.1 HD
8 M 20 ARPKD – 4.2 HD
9 M 14 FSGS – 3.5 HD
aSeven patients had developed ESRF and were undergoing hemodialysis (HD). Two children presented severe renal lesions
but were still on a conservative treatment. ARPKD, autosomal recessive polycystic kidney disease; LES, lupus erythmatosus
systemic; PD, peritoneal dialysis; TIN, tubulointerstitial nephropathy.
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horseradish peroxidase was used to determine biotin incorporation
with 2-(4-hydroxyazobenzene)-benzoic acid using the EZ Biotin Quan-
titation Kit (Pierce) at 500 nmwith correction for the amount of albumin
as determined by Coomassie R-250. A calibration curve that consisted
of four dilutions of the same serum with known concentration of
albumin was used as standard. Specificity of the maleimide dye for the
free SH group of Cys 34 was demonstrated by preventing the binding
with methyl-methanethiosulfonate that specifically binds this group at
pH 5.
Albumin Degradation In Vitro
A total of 100 g of purified albumin was incubated at 37°C for 16 h
with 0.1 g/ml (wt/vol) of bovine trypsin in a medium that contained
50 mM Tris-HCl (pH 7.8) and 5 mm CaCl2. The digestion was stopped
by addition of Laemmli reducing sample buffer (10 mM Tris-HCl [pH
8.8], 1% [wt/vol] SDS, 1 mM EDTA, 20% [vol/vol] glycerol, and 5%
[vol/vol] -mercaptoethanol) (26). After 1 h, the samples were loaded
on 8 to 18% (wt/vol) gradient SDS-PAGE and run at 45 mA at 12°C. Gel
was fixed with 40% (vol/vol) ethanol and 10% (vol/vol) acetic acid and
stained by silver nitrate.
Albumin Gene DNA Sequence
Genomic DNA was extracted from patient blood. The 14 coding
exons of human albumin gene and their intro-exon junctions were
PCR-amplified with specific primer pairs as already described by
Watkins et al. (27). Amplicons were purified by Exo-SAP-IT (Amersham
Bioscience, Milan, Italy) and directly subjected to direct sequencing
(ABI 3100; Applera, Milan, Italy).
Glutathione Assay
Reduced glutathione (GSH) levels were determined in plasma and in
red blood cells after trichloroacetic precipitation (28% wt/vol). GSH
was determined by dithio-bis (2-nitrobenzoic acid) at 412 nm with
correction with a blank reagent and using free cysteine as the standard
(28).
Statistical Analyses
Simple statistical tests based on one-way ANOVA and 2 test were
used to verify differences in free SH titration and N-A transition among
different cohorts of patients. Data are mean  SEM.
Results
Chemical and Structural Characterization of Plasma
Albumin in FSGS
The structural approach to plasma albumin in FSGS was
done originally in seven patients, using LC-ESI-MS/MS analy-
sis after reduction and alkylation of purified albumin (20). This
approach is not readily applicable for extensive analysis, be-
cause the sulfonic group at Cys 34 that is generated upon
oxidation is a stable end product in the native protein but may
undergo further rearrangements during alkylation (personal
observation by G.C.). Therefore, we devised a new proteomic
approach to plasma albumin that was based on characterization
by LC-ESI-MS/MS of trypsin digestion products of the native
protein that are more stable then the alkylated products and
gave highly reproducible results. Proteomic analysis of plasma
albumin now was extended to 12 patients with FSGS, five with
the idiopathic form and seven with posttransplantation recur-
rence of the disease. In the first step, albumin was purified in
nondenaturing conditions using preparative electrophoresis in
native gels giving a mean recovery yield 90%. Fine structure
analysis by LC-ESI-MS/MS and determination of the exact
mass by ESI-MS protein analysis then was repeated in all
patients.
LC-ESI-MS/MS. The spectrum of albumin after digestion
with trypsin indicated the presence of a parent fragment m/z
827.96 (K.ALVLIAFAQYLQQCSO3PFEDHVK.L) in the triply
charged state. The m/z 827.96 compound was studied by
MS/MS showing the presence of an m/z 511.71 ion in triple
charge that was consistent with a sequence in which the Cys 34
brings three additional oxygen residues, indicating oxidation of
the SH to cysteic acid (48; Figure 1). Control albumin was
characterized by the absence of the m/z 827.96 ion in triple
charge. In Table 5 are reported the sequences with relative Xcorr
and Cn of the MS/MS characterization of the m/z 827.96 ion
in the cohort of patients with primary nephrotic syndrome and
post-transplant recurrence. Xcorr and Cn were in all cases
highly significant, confirming the presence of a cysteic group in
position 34.
Table 4. Clinical and biochemical parameters in patients with different primary renal pathologies involving the
glomerulusa
Pathology n Gender Age(yr)
Onset
(yr)
Proteinuria
(g/d)
Serum
Creatinine
(mg/dl)
Serum
Albumin
(g/dl)
Class Therapy:St/CsA/ACEi
MGN 8 5 M, 3 F 39 (12 to 55) 36 (10 to 53) 6.0 (1.0 to 8.0) 1.1 (0.5 to 1.4) 1.5 (1.2 to 2.0) Class I: 1
Class II: 2
Class III: 4
Class IV: 1
7/0/6
MPGN 4 3 M, 1 F 14 (8 to 16) 9 (6 to 12) 2.5 (0.5 to 4.0) 0.8 (0.6 to 1.0) 3.2 (2.8 to 4.0) – 4/0/4
IgA 5 3 M, 2 F 42 (18 to 56) 25 (12 to 35) 	0.5 0.9 (0.5 to 1.2) 3.8 Class II: 3
Class III: 2
1/0/3
aOverall, 17 patients were enrolled. They were selected among the most frequent causes of glomerular diseases that cause
nephrotic syndrome (MGN), intermediate proteinuria (membrane proliferative glomerulonephritis 
MPGN) and hematuria
(IgA).
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ESI-MS. Analysis of the exact mass of plasma albumin was
used to confirm the result of the structural analysis in a large
cohort of patients. In all patients with FSGS, the bulk of plasma
albumin presented an exact mass of 66.555 kD, whereas this
isoform was only minimally detected in normal plasma in
which the major band presents a mass of 66.507 kD (data not
shown).
Biomarkers of Albumin Oxidation in Patients with FSGS/IgM
On the basis of sulfonic transformation, the free SH of Cys 34
of albumin should not be titrated any more and could become
a specific marker of oxidation. We devised a method for direct
“in gel” determination of free Cys 34 in plasma that could be
used in screening analysis. In this technique, the free Cys of
albumin was targeted by maleimide-PEO2 biotin, and the reac-
tion then was revealed by streptavidin. This assay was ex-
tended, with the analysis of N-A transition by electrophoretic
titration curves (24), to the whole cohort of patients. Overall, 23
patients with primary FSGS/IgM and florid proteinuria and 14
who were presenting posttransplantation recurrence of protein-
uria were studied. Ten patients with FSGS/IgM in stable re-
mission and four who received a renal transplant but were free
from recurrence represented the negative control group for
disease activity.
Cys 34 Titration. The results are given in Figure 2, the
former reporting an example of in gel titration in a selection of
patients from each separate clinical subset as above. It is evi-
dent the lack of albumin band in the PEO2-maleimide gel in
patients with proteinuria (see boxes in Figure 2). Figure 3
reports extensive results that confirm a marked decrease of Cys
34 titration in all patients with FSGS and IgM in both pre- and
posttransplantation phases compared with normal people and
with MGN with some differences within categories. In partic-
ular, patients with active FSGS and IgM had markedly lower
levels than in the remission phase (0.43  0.12 and 0.230  04
versus 1.94  0.42 U; P 	 0.003 and P 	 0.001, respectively);
patients with posttransplantation recurrence showed only
mildly lower levels than in patients with no recurrence (0.27 
0.04 versus 0.71  0.19). Normal people and other nephrotic
patients with MGN had instead the same concentration (normal
control subjects 2.75  0.33; MGN 2.48  0.67). For other
categories of renal diseases, see below. Overall, in patients with
active FSGS/IgM, Cys 34 seems massively oxidized, whereas
during the remission phase, a normal albumin pool is reconsti-
tuted.
N-A Transition. The rationale and the technique to define
N-A transition have been described extensively (24). Briefly,
changes in electrical charge were determined by an electro-
Figure 1. Mass spectrometry analyses of plasma albumin in
FSGS. Example of LC-ESI-MS/MS spectrum of the Cys 34
tryptic fragments of albumin from a patient with FSGS. Albu-
min that was purified from the patient showed, after digestion
with trypsin, the parent fragments mass-to-charge ratio (m/z)
511.7 in triply charged state, indicating the formation of a
cysteic residue in place of the sulfhydryl group in position 34 of
albumin. Analysis of control albumin did not reveal the forma-
tion of the m/z 511.7 fragment because of lack of ionization of
nonoxidized free sulfhydryl groups (SH).
Table 5. Sequence of the m/z 827.96 ion deriving from trypsin fragmentation of albumin that was purified from
patients with FSGSa
Patient Peptide Xcorr  Cn
1 K.ALVLIAFAQYLQQC*PFEDHVK.L 6.35 0.97
2 K.ALVLIAFAQYLQQC*PFEDHVK.L 6.55 0.99
3 K.ALVLIAFAQYLQQC*PFEDHVK.L 6.03 0.95
4 K.ALVLIAFAQYLQQC*PFEDHVK.L 4.85 0.99
5 K.ALVLIAFAQYLQQC*PFEDHVK.L 5.95 0.98
6 K.ALVLIAFAQYLQQC*PFEDHVK.L 6.55 0.97
7 K.ALVLIAFAQYLQQC*PFEDHVK.L 6.02 0.95
8 K.ALVLIAFAQYLQQC*PFEDHVK.L 4.78 0.98
9 K.ALVLIAFAQYLQQC*PFEDHVK.L 6.31 0.99
10 K.ALVLIAFAQYLQQC*PFEDHVK.L 5.87 0.98
11 K.ALVLIAFAQYLQQC*PFEDHVK.L 4.58 0.93
12 K.ALVLIAFAQYLQQC*PFEDHVK.L 5.74 0.97
aIn the case of normal albumin, no ions with this m/z could be detected in triple charge. MS/MS in triple charge of this
ion demonstrated the presence of a cysteic acid residue with m/z 511.7. Xcorr and Cn were in all cases highly significant and
probative for the chemical characterization above. C*, cysteic acid; Cn, correlation value; MS/MS, tandem mass spectrometry;
m/z, mass-to-charge ratio; Xcorr, cross-correlation.
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phoretic technique that measures changes in isoelectric point at
any given pH from 4 to 9. This technique also gives an estimate
of the amount of the protein with a charge change that is
inferred from the formation of isoform with different electro-
phoretic behavior. In all of the cases studied, the variation in
electrical charge involved 100% of the protein, and Figure 4A
shows an example of this change. Overall, the screening for
N-A transition confirmed the data on SH titration with some
difference for patients without posttransplantation recurrence.
In fact, N-A transition was common to all patients with active
FSGS and IgM and to those with posttransplantation recur-
rence, whereas, in the absence of proteinuria, in patients with-
out posttransplantation, recurrence and in patients with MGN,
a normal electrophoretic behavior was reconstituted. The per-
centage of patients with N-A transition in the various groups is
illustrated in Figure 4C and clearly shows a difference among
categories. Table 6 reports the mean  SD of ionization param-
eters reproducing experimental curves of 10 normal control
subjects and patients with proteinuria, according to the Linder-
stro¨m-Lang equation. Considering the parameters reported in
Table 6, this difference can be attributed to the presence of a
sulfonic group in position 34 of the sequence that modifies our
original assumption reported previously (24).
Titration of Albumin Cys 34 in Patients with ESRF and
with Other Glomerular Diseases
A few other groups of patients with different renal diseases
were enrolled and used for demonstrating the specificity for
FSGS of sulfonation of albumin Cys 34. The following groups of
patients were enrolled (Tables 3 and 4): (1) Nine patients with
chronic renal failure, two of whom were still on a conservative
regimen; (2) four children with primary MPGN; and (3) five
patients with IgA. In all cases, a normal titration of Cys 34 by
PEO2-maleimide was observed. The results presented in Figure
5 show a typical pattern of albumin staining with the dye. It
was found that maleimide staining, in particular, is specific for
the free SH group of Cys 34 because was abolished by prein-
Figure 2. Titration of the Cys 34 free SH groups of albumin in FSGS, IgM, and membranous glomerulonephritis (MGN). Titration
of albumin free SH 34 by a direct “in gel” technique that uses PEO2-maleimide-biotin (top) as a specific label. According to this
method, plasma proteins first are labeled with PEO2-maleimide-biotin and then are separated by monodimensional electrophore-
sis in nondenaturing conditions. After separation, the reaction is developed with streptavidin. Albumin from healthy people
showed PEO2-maleimide staining corresponding to albumin (arrows), whereas albumin of patients with FSGS had no staining,
indicating absence of a free SH that is unique in albumin at position 34 of the sequence (boxes). To prove specificity of the
maleimide staining for the free SH, one sample had been treated previously with methyl-methanethiosulfonate (MMTS) that
specifically blocked the free SH and prevented the maleimide binding.
Figure 3. Estimation of Cys 34-free SH group of albumin in the
whole cohort of patients with FSGS, IgM, andMGN. Results are
expressed as arbitrary unit of biotin per milligram of albumin.
A calibration curve with several dilutions of the same plasma
was prepared to obtain a confidence limit for linearity of the
assay.
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cubation of the protein with methyl-methanethiosulfonate at
pH 5.
Albumin Gene DNA Sequence
The 14 coding exons of human albumin gene and their intro-
exon junctions were sequenced in all patients who were en-
rolled in the study. In all cases, normal sequence was found,
excluding a genetic basis for altered oxidation.
Susceptibility to Digestion by Trypsin
Because the antioxidation effect of albumin has been consid-
ered for a long time a suicidal reaction that modifies suscepti-
bility to digestion by common proteases, albumin was purified
from plasma of four patients with idiopathic FSGS and four
with posttransplantation recurrence and submitted to mild di-
gestion with trypsin (see the Materials and Methods section).
The results reported in Figure 6 demonstrate the formation of
fragments in the majority of affected cases, confirming the
original assumption (lanes f through n). Normal albumin was
not digested following the same conditions (lanes a through e).
GSH in Plasma and in Erythrocytes
GSH levels were determined in plasma and in red blood cells
of proteinuric patients with FSGS and in control subjects. Lev-
els were slightly decreased in patients with active nephrotic
syndrome compared with control subjects in both plasma
(8.1  0.2 versus 8.4  mol/L) and in red blood cells (6.8  0.8
versus 7.5  0.8 nmol/mg hemoglobin), but the difference did
not reached statistical significance because of the low number
of cases.
Figure 4. Electrophoretic titration curves for neutral to acid N-A
transition. (A) Example of electrophoretic titration curve of a
plasma sample from a patient with FSGS and for comparison of
normal plasma stained with Coomassie R-250. The two proteins
migrate as a single and homogeneous band throughout the pH
range: Between 4 and 4.5 and between 7 and 9, they overlap,
whereas in the pH range between 4.5 and 7, oxidized albumin
migrates with a more acid charge. (B) Theoretical electro-
phoretic curve of albumin in which a cysteic group replaces a
free sulfhydryl residue. According to the Linderstro¨m-Lang
theory, this acid charge shift fits with the introduction of a
sulfonic acid group in the molecule. Determination of albumin
charge along a stable pH gradient was done according the
procedure described by Bruschi et al. (24). (C) Percentage of
patients with N-A transition in patients with nephrotic syn-
drome and different clinical activity. Presence and/or absence
of fast albumin in the pH range 4.5 and 7 was evaluated in all
patients that was defined in positive cases as N-A transition.
Bars indicate the percentage of patients with N-A transitions in
different study cohorts.
Table 6. Ionization parameters of healthy and oxidized
albumin calculated according to Linderström-Lang
equationa
Groups
Healthy Albumin Oxidized Albumin
n° pK°m n° PK°m
-COOH 1 3.8 0.2 1 3.8 0.3
r-COOH 96 4.00 0.02 96 4.00 0.03
Tiolic 1 8.0 0.3 1 8.0 0.2
Phenolic 18 10.2 0.2 18 10.2 0.3
Imidazole 2 6.24 0.01 2 6.23 0.01
-Amino 1 7.80 0.02 1 7.80 0.02
-Amino 59 10.4 0.4 59 10.4 0.5
Guanidyl 24 12 24 12
Sulfonic 0 – 1 6.23 0.01
pI 4.79  0.01 4.68 0.01
an°, number of ionizable amino acid; pK°m, pK° medium
of ionizable amino acid.
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Discussion
The underlying mechanism of antioxidant response in living
systems has been investigated widely for a long time. Several
aspects related to antioxidant response in human plasma re-
main unresolved because, despite comparable or even in-
creased exposure to oxidants, plasma levels of major intracel-
lular antioxidant molecules such as GSH and related enzymes
are much lower than in the intracellular compartment (0.006
versus 0.75 mM/L). Studies that used in vitro models of oxida-
tion convincingly indicated that plasma albumin is involved in
plasma antioxidant activity by means of the unique free sulf-
hydryl groups of Cys 34 that is transformed into a sulfonic
group by oxidation. In vitro models also suggest that the inter-
mediate of the reaction is a sulfenic (SOH-alb) that in vivo may
rapidly react with free GSH to form nonmercapto albumin or
form dimers of the protein (29). Overall, this reaction should
involve 20 to 25% of albumin that is the amount of nonmer-
capto plus dimeric albumin in plasma. Even if in vitro studies
furnish a solid chemical background to a participation of albu-
min into the antioxidant response in plasma, evidence that
albumin oxidation takes place in vivo has never been reported,
with the exception of scattered reports of partial albumin oxi-
dation in ESRF (30) and diabetes that had been obtained with
indirect techniques (31,32). Studies in patients with ESRF are of
particular interest because they show the increase of nonmer-
captoalbumin that should represent the product of reaction of
free plasma thiols such as GSH and/or homocysteine with the
sulfenic derivative of albumin. The quota of sulfenic albumin in
patients with ESRF is estimated to represent less than the 5% of
total albumin. In this study, we demonstrate for the first time
that plasma albumin in patients with active FSGS undergoes
massive and stable oxidation with chemical modification of the
unique free SH of Cys 34 to a sulfonic group (SO3
) that is an
end product of the reaction. This change involves some relevant
alterations of the protein with formation of an adduct with
48-Da molecular weight, changes of the net charge as a result
of additional negative residues, and loss of free SH titration.
Therefore, in vivo plasma oxidation produces a more stable
derivative than the one described in in vitro models, and, most
important, SO3
-alb does not dimerize but undergoes proteol-
ysis. This later event may be considered a suicidal effect that
results in albumin removal from plasma. Accordingly, many
albumin fragments can be detected in urine of patients with
FSGS. As a whole, these data demonstrate that oxidation of
plasma albumin occurs in vivo, and this is the first demonstra-
tion of what seems to be a crucial physiologic process. Overall,
the process of oxidation of albumin in FSGS seems substantially
different from oxidation that is reported in patients with ESRF
because, as already discussed, it mainly involves only the for-
mation of an instable intermediate in this condition. According
to the literature on the topic (31,32), the amount of sulfonic end
product in patients with ESRF is approximately 5% of total
albumin and is under the limit of sensitivity of the maleimide
assay. Lack of observation of this peculiar structural modifica-
tion on the basis of a direct spectroscopic approach in other
cohorts of patients with primary and secondary glomerulone-
phritis with and without nephrotic syndrome and in young
adults with ESRF suggests, therefore, a good degree of speci-
ficity for FSGS.
This key observation leads to two considerations. The first is
that albumin, as a result of the high plasma levels, is the major
antioxidant substance in plasma and is higher than other anti-
oxidants. In other words, the molar level of the free SH of Cys
Figure 5. Titration of the Cys 34 free SH group of albumin by the
PEO2-maleimide technique in patients with end-stage renal
failure (A) and in other patients with type 1 membranoprolif-
erative glomerulonephritis (B) or with IgA (C). The two young-
est patients of the cohort with renal failure were maintained on
a conservative treatment, whereas seven were treated with
hemodialysis (see Table 3). Also in this case, specificity of
maleimide for the free SH of Cys 34 was proved by inhibition
of the binding with MMTS that is specific for this group (see
sample 10 [MMTS] in A).
Figure 6. Susceptibility to fragmentation of albumin that was
purified from patients and control subjects. Albumin after purifi-
cation was incubated with trypsin as indicated in the Materials
andMethods section. Lanes a through e indicate albumin that was
purified from normal control subjects; lanes f through i indicate
albumin that was purified from patients with active FSGS; lanes j
through m indicate albumin that was purified from patients with
posttransplantation recurrence of proteinuria.
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34 of albumin is higher than free GSH by a factor of 100 (0.8
versus 0.008 mM). Second, massive oxidation of plasma albu-
min implicates new pathogenic mechanisms in FSGS related to
oxidation. In this view, data deriving from the determination of
biomarkers of albumin oxidation (SH titration and N-A transi-
tion) suggest some clinical correlations: (1) In pretransplanta-
tion patients, oxidation is associated with proteinuria, whereas
in patients with stable remission, there is a clear trend to
normalization; (2) the effect of the nephrotic syndrome per se
can be ruled out on the basis of data on patients with MGN; and
(3) patients with posttransplantation recurrence also present
the same signs of albumin oxidation that are attenuated in
absence of recurrence. Lack of complete normalization of free
SH in patients in stable relapse and in those who do not have a
recurrence could suggest presence of oxidants at lower levels,
but we cannot readily exclude that albumin in patients with
FSGS/IgM have a stable reduction in antioxidation potential.
This is a central point because an altered response of albumin to
oxidation could represent a potential trigger of renal toxicity.
However, albumin gene sequence in patients with FSGS did not
reveal any mutants or sequence variants, ruling out the possi-
bility of a primary defect involving albumin structure. The
finding of massive oxidation of albumin in patients with active
FSGS also suggests that free radicals are produced in excess in
these patients. Several literature data on both human and ex-
perimental FSGS strongly support the implication of free rad-
icals. In fact, practically all animal models of nongenetic FSGS
are based on free radical generation. They include puromycin
and Adriamycin nephrosis in rats and Mvp 17 / mice (33–
37). Renal infusion of H2O2 also induces proteinuria in rats and
upregulates the expression of factors such as C/EBP homology
protein (GADD 153) that also are upregulated in human FSGS
and rat puromycin nephrosis (38). The Adriamycin model is of
particular interest because the quinone structure of the mole-
cule allows a direct participation in redox reaction (39,40) and
may act directly as a free radical.
Few data on free radical generation during nephrotic syn-
drome are available in humans. However, increased oxidation
for inherited defects that are associated with coenzyme Q de-
ficiency as in the case of CoQ2 mutations produces renal lesions
that resemble FSGS (41). Increased peroxidation of membrane
lipids and consumption of intraerythrocyte GSH in children
with FSGS also support an implication of free radicals (28,42);
however, these changes are only indirect and reflect peroxida-
tion by lipophilic substances that probably are not involved
here. In this context, a central point is the type of oxidant
involved. Several studies that investigated the structural effect
of various oxidants on plasma proteins in vitro (43,44) clearly
indicated that oxidation of thiol groups is specific of N-chlora-
mine derivatives of -amino acids. In contrast, HOCl reacts
preferentially with methionine residues and with ascorbate,
and more lipophilic -chloramines are able to cross cell mem-
branes and oxidize intracellular components such as GSH and
hemoglobin. Because N-chloramines derive from the reaction
of HOCl that is produced by phagocytes and free amino acids,
we hypothesized that phagocytes are the source of oxidants in
FSGS. Stability and reactivity of N-chloramines differ depend-
ing on their structure, but -chloramines are more stable than
other similar compounds and probably propagate damage
from the source of HOCl. Their half-life, however, is in the
order of a few minutes, and we have no chance to demonstrate
high levels of N-chloramines in plasma of patients. Analysis of
sulfonation of the free Cys 34 SH may serve as a good way to
reveal their effect, and we propose a wider utilization for
clinical and experimental studies.
The observation of massive oxidation of albumin in FSGS
and the possibility to have readily available laboratory assays
may lead to preemptive therapy before the development of
massive proteinuria. Our finding also lends support to the
current use of plasmapheresis for recurrence of FSGS. The
success of plasmapheresis in inducing remission of proteinuria
in patients with recurrent FSGS may be due to exchange of
albumin (replacement of oxidized with normal albumin) rather
than the assumed removal of a circulating permeability factor.
Conclusion
These data demonstrate massive oxidation of plasma albu-
min in patients with FSGS that induces stable sulfonation of
Cys 34. Oxidation of albumin is associated with disease activity
and posttransplantation recurrence of proteinuria. The analyt-
ical methods that we have described allow rapid determination
of albumin oxidation and may lead to prompt therapeutic
intervention.
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